Discover 5 insights about psoriatic arthritis from rheumatology experts, including pain management strategies, treatment ...

A rheumatologist discusses how her understanding of chronic pain in PsA has evolved—and how it affects her approach to ...

Visible signs of psoriatic arthritis appear months and even years before a person develops the full-blown inflammatory joint ...

Pharma advertisers have kicked off 2025 with a bang, with the top 10 spenders throwing almost 30% more money behind their TV ...

Having psoriasis raises your risk of psoriatic arthritis — and rheumatoid arthritis, too. Make sure you can tell these two forms of arthritis apart.

This is a developing news story. Please check back soon for updates. Tremfya reduced signs and symptoms of psoriatic ...

Following the study, the FDA approved the use of Tremfya to treat moderately to severely active ulcerative colitis. In September 2024, the University of Chicago Medicine became the first hospital in ...

Johnson & Johnson (J&J) has shared positive results from a phase 3b study of Tremfya (guselkumab) in adults with psoriatic ...

Long-term extension analysis of the phase 3b APEX study (NCT04882098) through 3 years of treatment will further assess the ...

AbbVie’s Skyrizi and Rinvoq were practically unshakeable atop the monthly TV drug ad spending rankings, ultimately leading ...

Long-term extension data show Tremfya (guselkumab) significantly reduced symptoms and inhibited structural joint damage progression in patients with active psoriatic arthritis.

US-based pharmaceutical company Johnson & Johnson (J&J) has reported positive results from a Phase IIIb trial of its ...